WO2009090556A8 - Reproduction artificielle des conditions pharmacologiques de la dépendance au tabac et à d' autres drogues toxicomanogènes (opiacés, psychostimulants, alcool) par la combinaison de nicotine et d'un ligand (agoniste ou 5 antagoniste) des récepteurs 5-ht1a - Google Patents
Reproduction artificielle des conditions pharmacologiques de la dépendance au tabac et à d' autres drogues toxicomanogènes (opiacés, psychostimulants, alcool) par la combinaison de nicotine et d'un ligand (agoniste ou 5 antagoniste) des récepteurs 5-ht1a Download PDFInfo
- Publication number
- WO2009090556A8 WO2009090556A8 PCT/IB2009/000468 IB2009000468W WO2009090556A8 WO 2009090556 A8 WO2009090556 A8 WO 2009090556A8 IB 2009000468 W IB2009000468 W IB 2009000468W WO 2009090556 A8 WO2009090556 A8 WO 2009090556A8
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- nicotine
- tobacco
- market
- addictive
- products
- Prior art date
Links
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 title abstract 9
- 229960002715 nicotine Drugs 0.000 title abstract 9
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 title abstract 9
- 241000208125 Nicotiana Species 0.000 title abstract 7
- 235000002637 Nicotiana tabacum Nutrition 0.000 title abstract 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 title abstract 3
- 229940079593 drug Drugs 0.000 title abstract 3
- 239000003814 drug Substances 0.000 title abstract 3
- 239000003368 psychostimulant agent Substances 0.000 title abstract 3
- 102000017911 HTR1A Human genes 0.000 title 1
- 101150015707 HTR1A gene Proteins 0.000 title 1
- 239000000556 agonist Substances 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- 239000003446 ligand Substances 0.000 title 1
- 230000000694 effects Effects 0.000 abstract 6
- 238000006467 substitution reaction Methods 0.000 abstract 4
- SNPPWIUOZRMYNY-UHFFFAOYSA-N bupropion Chemical compound CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 SNPPWIUOZRMYNY-UHFFFAOYSA-N 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 229960004751 varenicline Drugs 0.000 abstract 3
- 229940123685 Monoamine oxidase inhibitor Drugs 0.000 abstract 2
- 239000000654 additive Substances 0.000 abstract 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 abstract 2
- 239000002899 monoamine oxidase inhibitor Substances 0.000 abstract 2
- 230000000391 smoking effect Effects 0.000 abstract 2
- TWYFGYXQSYOKLK-CYUSMAIQSA-N varenicline tartrate Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.C12=CC3=NC=CN=C3C=C2[C@H]2C[C@@H]1CNC2 TWYFGYXQSYOKLK-CYUSMAIQSA-N 0.000 abstract 2
- 229940018503 zyban Drugs 0.000 abstract 2
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 abstract 1
- USSIQXCVUWKGNF-UHFFFAOYSA-N 6-(dimethylamino)-4,4-diphenylheptan-3-one Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 USSIQXCVUWKGNF-UHFFFAOYSA-N 0.000 abstract 1
- 229940122820 Cannabinoid receptor antagonist Drugs 0.000 abstract 1
- 206010012335 Dependence Diseases 0.000 abstract 1
- 102000010909 Monoamine Oxidase Human genes 0.000 abstract 1
- 108010062431 Monoamine oxidase Proteins 0.000 abstract 1
- 206010067482 No adverse event Diseases 0.000 abstract 1
- 229940025084 amphetamine Drugs 0.000 abstract 1
- 230000000903 blocking effect Effects 0.000 abstract 1
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 abstract 1
- 229960001736 buprenorphine Drugs 0.000 abstract 1
- UAIXRPCCYXNJMQ-RZIPZOSSSA-N buprenorphine hydrochlorie Chemical compound [Cl-].C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)C[NH+]2CC1CC1 UAIXRPCCYXNJMQ-RZIPZOSSSA-N 0.000 abstract 1
- 229960001058 bupropion Drugs 0.000 abstract 1
- 239000003536 cannabinoid receptor antagonist Substances 0.000 abstract 1
- 229940112822 chewing gum Drugs 0.000 abstract 1
- 235000015218 chewing gum Nutrition 0.000 abstract 1
- 229960003920 cocaine Drugs 0.000 abstract 1
- 230000007812 deficiency Effects 0.000 abstract 1
- 230000002526 effect on cardiovascular system Effects 0.000 abstract 1
- 229960001797 methadone Drugs 0.000 abstract 1
- 231100000252 nontoxic Toxicity 0.000 abstract 1
- 230000001846 repelling effect Effects 0.000 abstract 1
- JZCPYUJPEARBJL-UHFFFAOYSA-N rimonabant Chemical compound CC=1C(C(=O)NN2CCCCC2)=NN(C=2C(=CC(Cl)=CC=2)Cl)C=1C1=CC=C(Cl)C=C1 JZCPYUJPEARBJL-UHFFFAOYSA-N 0.000 abstract 1
- 229960003015 rimonabant Drugs 0.000 abstract 1
- 230000002295 serotoninergic effect Effects 0.000 abstract 1
- 208000019116 sleep disease Diseases 0.000 abstract 1
- 239000000779 smoke Substances 0.000 abstract 1
- 229940095172 subutex Drugs 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
- JQSHBVHOMNKWFT-DTORHVGOSA-N varenicline Chemical compound C12=CC3=NC=CN=C3C=C2[C@H]2C[C@@H]1CNC2 JQSHBVHOMNKWFT-DTORHVGOSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/465—Nicotine; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Cette invention permet non seulement aux fumeurs d'arrêter de consommer du tabac, sans limitation de durée et sans encourir d'effets indésirables importants, mais aussi aux consommateurs de drogues toxicomanogènes en général (opiacés, psychostimulants, alcool) d'arrêter la consommation des drogues concernées. CONTEXTE DE L'INVENTION. Sur le marché, les produits utilisés dans la lutte contre le tabagisme sont de trois types : a. les apports de nicotine (patch, gomme à mâcher...) : La nicotine n' a pas d' effet toxique mais les apports de nicotine seule n'ont un effet significatif sur la consommation de tabac que pendant les premières semaines de traitement. Les rechutes sont très fréquentes (supérieures à 75 %). b. le Zyban (Bupropion) : Le Zyban, consommé avec ou sans nicotine, n'agit pas comme un substitut addictif. Sur le plan clinique, on constate 80% de rechute après un mois de traitement. Il a de plus des effets cardiovasculaires indésirables. c. le Champix (la Varénicline): Le Champix est de commercialisation récente. Il a pour fonction d'inhiber en partie l'effet de la nicotine. Il n'agit pas comme substitut addictif. Sur le plan clinique, les taux d'arrêt communiqués jusqu'à présent sont de l'ordre de 44% après un mois, avec des niveaux de rechute dans les mois qui suivent très importants. Des effets secondaires non négligeables tels que les troubles du sommeil sont décrits depuis sa mise sur le marché. Les principales recherches actuel
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR08/00189 | 2008-01-14 | ||
| FR0800189A FR2926221A1 (fr) | 2008-01-14 | 2008-01-14 | Compositions permettant la reproduction artificielle des conditions pharmacologiques de la dependance aux drogues addictives telles que opiaces, psychostimulants, tabac et alcool, par la combinaison de nicotine et d'un ligand. |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| WO2009090556A2 WO2009090556A2 (fr) | 2009-07-23 |
| WO2009090556A8 true WO2009090556A8 (fr) | 2009-10-01 |
| WO2009090556A3 WO2009090556A3 (fr) | 2010-01-07 |
Family
ID=39671393
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/IB2009/000468 WO2009090556A2 (fr) | 2008-01-14 | 2009-03-09 | Reproduction artificielle des conditions pharmacologiques de la dépendance au tabac et à d' autres drogues toxicomanogènes (opiacés, psychostimulants, alcool) par la combinaison de nicotine et d'un ligand (agoniste ou 5 antagoniste) des récepteurs 5-ht1a |
Country Status (2)
| Country | Link |
|---|---|
| FR (1) | FR2926221A1 (fr) |
| WO (1) | WO2009090556A2 (fr) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011023796A1 (fr) * | 2009-08-31 | 2011-03-03 | Abbott Healthcare Products B.V. | Bifeprunox destiné au traitement de l'addiction |
| AU2013288265B2 (en) | 2012-07-09 | 2017-04-06 | Lupin Limited | Tetrahydroquinazolinone derivatives as PARP inhibitors |
| US11977085B1 (en) | 2023-09-05 | 2024-05-07 | Elan Ehrlich | Date rape drug detection device and method of using same |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL110857A0 (en) * | 1993-09-09 | 1994-11-28 | Lilly Co Eli | Cessation of tobacco use |
| GB9812941D0 (en) * | 1998-06-16 | 1998-08-12 | Smithkline Beecham Plc | Method of treatment |
| DE10018834A1 (de) * | 2000-04-15 | 2001-10-25 | Lohmann Therapie Syst Lts | Transdermale oder transmucosale Darreichungsformen mit einer nicotinhaltigen Wirkstoffkombination zur Raucherentwöhnung |
| AU2001218105B2 (en) * | 2000-12-01 | 2005-10-06 | Be Able, Llc | Behavior chemotherapy |
| US20040037879A1 (en) * | 2001-11-02 | 2004-02-26 | Adusumilli Prasad S. | Oral controlled release forms useful for reducing or preventing nicotine cravings |
-
2008
- 2008-01-14 FR FR0800189A patent/FR2926221A1/fr not_active Withdrawn
-
2009
- 2009-03-09 WO PCT/IB2009/000468 patent/WO2009090556A2/fr active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| WO2009090556A3 (fr) | 2010-01-07 |
| FR2926221A1 (fr) | 2009-07-17 |
| WO2009090556A2 (fr) | 2009-07-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Bhisey | Chemistry and toxicology of smokeless tobacco | |
| WO2007091181A3 (fr) | Additifs à libération d'arômes à base de gamma-cyclodextrine | |
| WO2007056284A3 (fr) | Compositions viscoelastiques polycationiques | |
| WO2008132600A3 (fr) | Antagonistes de trpv1 et utilisations de ceux-ci | |
| DK1458252T3 (da) | Tobak og/eller tobak i kombination med tobakssubstitutkomposition til anvendelse som snus i den orale kavitet | |
| MX2009007603A (es) | Insecticidas como safeners ara fungicidas con accion fitotoxica. | |
| WO2007104573A3 (fr) | Composition améliorée de tabac à priser | |
| BRPI0510909A2 (pt) | composto de ligaÇço fÁrmaco-ligante citotàxico, formulaÇço farmacÊutica, mÉtodo para matar uma cÉlula e mÉtodo para retardar ou interromper o crescimento de tumor | |
| WO2002100199A3 (fr) | Modification des taux de nicotine et de nitrosamine dans le tabac | |
| SG171601A1 (en) | Further medical uses of antisecretory protein | |
| Lewis et al. | Monoamine oxidase inhibitory activity in tobacco smoke varies with tobacco type | |
| WO2008089201A3 (fr) | Composés de pipéridine substituée hétérocycliques et leurs utilisations | |
| US10188139B2 (en) | Additives for tobacco cut filler | |
| WO2009090556A3 (fr) | Reproduction artificielle des conditions pharmacologiques de la dépendance au tabac et à d' autres drogues toxicomanogènes (opiacés, psychostimulants, alcool) par la combinaison de nicotine et d'un ligand (agoniste ou 5 antagoniste) des récepteurs 5-ht1a | |
| US20140261485A1 (en) | Inhibition of sensory irritation during consumption of smokeless tobacco products using a combinatorial approach | |
| Van der Kam et al. | Effect of 2-methyl-6-(phenylethynyl) pyridine on intravenous self-administration of ketamine and heroin in the rat | |
| MX2008013777A (es) | Usos medicos adicionales de la proteina antisecretora. | |
| SE9904413D0 (sv) | Comminuted form | |
| Chen et al. | Nicotine enhances alcoholic fatty liver in mice: Role of CYP2A5 | |
| WO2008010863A3 (fr) | Nouveau substitut de tabac | |
| WO2010066679A3 (fr) | Mélanges herbicides | |
| WO2007083196A3 (fr) | Incorporation de composes de liberation d'ammoniac dans des articles de tabac | |
| EP1735005B8 (fr) | Procede d'encapsulage de materiaux a ingestion orale afin de modifier le site de digestion, le site d'action ou la stabilite | |
| JP2006217820A (ja) | シガレット | |
| JP2006187260A (ja) | シガレット |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09702033 Country of ref document: EP Kind code of ref document: A2 |
|
| NENP | Non-entry into the national phase in: |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 09702033 Country of ref document: EP Kind code of ref document: A2 |